# Metrion Biosciences

Startup profile on Capital Atlas: https://capitalatlas.ai/startups/metrion-biosciences

- Industry: Pharmaceuticals
- Headquarters: Cambridge, UK
- Website: www.metrionbiosciences.com
- Total disclosed funding: $0.4M
- Latest round: Series A (Dec 17, 2018)
- Investors on record: 1

## About

Metrion Biosciences Limited is a UK-based contract research organization specializing in preclinical drug discovery services, focusing on ion channel screening and cardiac safety assessments to support pharmaceutical innovation.Founded in 2015 and headquartered in Cambridge, UK, Metrion Biosciences Limited provides comprehensive preclinical drug discovery services. The firm has successfully completed three investment rounds, with the latest round in December 2023 raising GBP 3.724 million led by Maven VCT and participated in by Gresham House, reaching a total amount raised of GBP 3.724 million. The company has maintained a consistent focus on preclinical assessments, particularly related to cardiac and neurological drug candidates.Metrion Biosciences specializes in high-quality preclinical drug discovery services, with a strong emphasis on ion channel screening, cardiac safety assessments, and neuroscience evaluations. Key offerings include the NaV1.9 high-throughput screening assay aimed at enhancing pain research, GLP hERG testing, hiPSC-derived cardiomyocyte screening for cardiac risk assessment, and a range of neuroscience translational assays. Their diverse client base encompasses pharmaceutical and biotechnology companies across North America, Europe, and Japan, facilitating the generation of critical preclinical data for drug development.In the most recent financial year 2023, Metrion Biosciences reported a revenue of GBP 7,510,661.40 with an EBITDA of GBP -563,971.60. The company generates income through tailored assay services billed according to project specifics, often involving fixed fees or milestone payments tied to research outcomes.Following its recent funding round in December 2023, Metrion Biosciences Limited plans to expand its laboratories in Cambridge and invest in specialized equipment to enhance its service offerings. The company aims to bolster its global marketing campaigns to penetrate new markets and regions. This strategic growth is supported by the GBP 3.72 million raised, enabling Metrion to continue advancing its capabilities in preclinical drug discovery.

## Funding rounds

- Series A, Dec 17, 2018, $0.4M — O2h Ventures

## Investors

- O2h Ventures (https://capitalatlas.ai/funds/o2h-ventures) — Series A